MX2016008304A - Usos de oligouronatos en el tratamiento de cancer. - Google Patents

Usos de oligouronatos en el tratamiento de cancer.

Info

Publication number
MX2016008304A
MX2016008304A MX2016008304A MX2016008304A MX2016008304A MX 2016008304 A MX2016008304 A MX 2016008304A MX 2016008304 A MX2016008304 A MX 2016008304A MX 2016008304 A MX2016008304 A MX 2016008304A MX 2016008304 A MX2016008304 A MX 2016008304A
Authority
MX
Mexico
Prior art keywords
oligouronates
cancer
relates
agent
treatment
Prior art date
Application number
MX2016008304A
Other languages
English (en)
Inventor
Taylor Nordgård Catherine
Draget Kurt
Original Assignee
Norwegian Univ Of Science And Tech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201322958A external-priority patent/GB201322958D0/en
Priority claimed from GB201410695A external-priority patent/GB201410695D0/en
Application filed by Norwegian Univ Of Science And Tech filed Critical Norwegian Univ Of Science And Tech
Publication of MX2016008304A publication Critical patent/MX2016008304A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Esta invención se refiere al uso de un oligouronato en el tratamiento o prevención de cáncer, tanto como un agente anticancerígeno, que es como un agente eficaz contra el cáncer en sí, y como herramienta de suministro de fármaco, que es para mejorar o promover el suministro de un agente anticancerígeno adicional o diferente, por ejemplo, fármaco de quimioterapia o agente inmunoterapéutico. Por lo tanto, la invención se refiere al uso en la prevención de cáncer o el tratamiento de oligouronatos tanto solos como en combinación con uno o más agentes anticancerígenos adicionales. La invención también se refiere a métodos para tratar o prevenir cáncer utilizando oligouronatos, ya sea solo o en combinación con uno o más agentes anticancerígenos adicionales.
MX2016008304A 2013-12-23 2014-12-23 Usos de oligouronatos en el tratamiento de cancer. MX2016008304A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201322958A GB201322958D0 (en) 2013-12-23 2013-12-23 Uses of oligouronates in cancer treatment
GB201410695A GB201410695D0 (en) 2014-06-16 2014-06-16 Uses of oligouronates in cancer treatment
PCT/EP2014/079178 WO2015097224A1 (en) 2013-12-23 2014-12-23 Uses of oligouronates in cancer treatment

Publications (1)

Publication Number Publication Date
MX2016008304A true MX2016008304A (es) 2017-01-09

Family

ID=52232205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008304A MX2016008304A (es) 2013-12-23 2014-12-23 Usos de oligouronatos en el tratamiento de cancer.

Country Status (7)

Country Link
US (1) US20160346313A1 (es)
EP (1) EP3086847A1 (es)
JP (1) JP2017501221A (es)
AU (1) AU2014372566B2 (es)
CA (1) CA2934950A1 (es)
MX (1) MX2016008304A (es)
WO (1) WO2015097224A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016113018A1 (de) * 2016-07-14 2018-01-18 Abbas Mirshafiey Pharmazeutische Verwendung von beta-D-Mannuronsäure
WO2018127819A1 (en) 2017-01-03 2018-07-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto
EP3600338A4 (en) 2017-03-28 2020-10-28 The University of North Carolina at Chapel Hill NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES
US10969135B2 (en) * 2017-07-27 2021-04-06 Johnson Controls Technology Company Central plant control system with computation reduction based on sensitivity analysis
JP2021515083A (ja) 2018-03-06 2021-06-17 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒルＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 生分解性の抗菌性足場としての一酸化窒素放出性シクロデキストリンおよびそれに関する方法
CA3124673A1 (en) 2018-12-28 2020-07-02 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4186294B2 (ja) * 1999-02-26 2008-11-26 セイコーエプソン株式会社 ポリグルロン酸の製造方法
JP2005145885A (ja) * 2003-11-14 2005-06-09 Japan Science & Technology Agency アルギン酸オリゴマーからなる免疫機構賦活剤
GB2430881B (en) * 2005-10-06 2010-10-13 Ntnu Technology Transfer As Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
JPWO2007069468A1 (ja) * 2005-12-14 2009-05-21 国立大学法人 長崎大学 サイトカイン分泌促進剤
US20100075918A1 (en) * 2006-12-08 2010-03-25 Lokeshwar Vinata B Hyaluronidase inhibitors as anti-cancer agents
GB0707096D0 (en) * 2007-04-12 2007-05-23 Ntnu Technology Transfer As Method
CA2706637C (en) * 2007-11-27 2016-11-29 Algipharma Ipr As Use of alginate oligomers in combating biofilms
GB0904942D0 (en) * 2009-03-23 2009-05-06 Ntnu Technology Transfer As Composition
GB0909529D0 (en) * 2009-06-03 2009-07-15 Algipharma Ipr As Alginate oligomers for the inhibition of microbial adherence to surfaces
JP2013010700A (ja) * 2011-06-28 2013-01-17 Meiji Univ ヒアルロニダーゼ阻害剤

Also Published As

Publication number Publication date
CA2934950A1 (en) 2015-07-02
US20160346313A1 (en) 2016-12-01
AU2014372566A1 (en) 2016-07-07
EP3086847A1 (en) 2016-11-02
AU2014372566B2 (en) 2017-07-20
JP2017501221A (ja) 2017-01-12
WO2015097224A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
MA39906A (fr) Polythérapies pour le traitement du cancer
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
MD20170073A2 (ro) Terapii combinate pentru tratarea cancerelor
TW201613887A (en) Antiproliferative compounds and methods of use thereof
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
NZ749218A (en) Androgen receptor modulator and uses thereof
MX2016008304A (es) Usos de oligouronatos en el tratamiento de cancer.
PH12016500511A1 (en) Selective grp94 inhibitors and uses thereof
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
SG11201802915WA (en) Cancer treatment composition combining anti-cd26 antibody and other anticancer agent
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2017015896A (es) Agente anticancerigeno.
CL2015003595A1 (es) Inhibidores/antiandrógenos novedosos de cyp17
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
PH12015502342A1 (en) Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer
MX2019005349A (es) Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos.
PH12015502815A1 (en) Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps)
MX2016015568A (es) Derivados de nucleosidos para el tratamiento del cancer.
TN2013000333A1 (en) Combinations comprising macitentan for the treatment of glioblastoma multiforme
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
PH12016501838A1 (en) Compounds and their methods of use
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
MX2017013666A (es) Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer.